Diabetes Metab J.  2022 Mar;46(2):239-256. 10.4093/dmj.2022.0013.

Links between Thyroid Disorders and Glucose Homeostasis

• Eom YS
• Wilson JR
• Bernet VJ

• KMID: 2527717
• DOI: http://doi.org/10.4093/dmj.2022.0013

Abstract

Thyroid disorders and diabetes mellitus often coexist and are closely related. Several studies have shown a higher prevalence of thyroid disorders in patients with diabetes mellitus and vice versa. Thyroid hormone affects glucose homeostasis by impacting pancreatic β-cell development and glucose metabolism through several organs such as the liver, gastrointestinal tract, pancreas, adipose tissue, skeletal muscles, and the central nervous system. The present review discusses the effect of thyroid hormone on glucose homeostasis. We also review the relationship between thyroid disease and diabetes mellitus: type 1, type 2, and gestational diabetes, as well as guidelines for screening thyroid function with each disorder. Finally, we provide an overview of the effects of antidiabetic drugs on thyroid hormone and thyroid disorders.

Keyword

Diabetes mellitus; Glucose; Homeostasis; Thyroid diseases; Thyroid hormones

Figure

• 

  Fig. 1. Maintenance of blood glucose levels by insulin and glucagon in fed and fasting states.

• 

  Fig. 2. Effects of thyroid hormone on glucose metabolism. GLUT4, glucose transporter type 4; PEPCK, phosphoenolpyruvate carboxykinase.

Reference

1. Nederstigt C, Corssmit EP, de Koning EJ, Dekkers OM. Incidence and prevalence of thyroid dysfunction in type 1 diabetes. J Diabetes Complications. 2016; 30:420–5.

2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87:489–99.

3. Gu Y, Li H, Bao X, Zhang Q, Liu L, Meng G, et al. The relationship between thyroid function and the prevalence of type 2 diabetes mellitus in euthyroid subjects. J Clin Endocrinol Metab. 2017; 102:434–42.

4. Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013; 8:e66711.

5. Gronich N, Deftereos SN, Lavi I, Persidis AS, Abernethy DR, Rennert G. Hypothyroidism is a risk factor for new-onset diabetes: a cohort study. Diabetes Care. 2015; 38:1657–64.

6. Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, Hegedus L. Type and extent of somatic morbidity before and after the diagnosis of hypothyroidism: a nationwide register study. PLoS One. 2013; 8:e75789.

7. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 2004; 17:183–90.

8. Roder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med. 2016; 48:e219.

9. Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon N, Karam J, et al. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. 1979; 236:E380–5.

10. Moore CX, Cooper GJ. Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun. 1991; 179:1–9.

11. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes. 1997; 105:187–95.

12. Levin BE, Routh VH, Kang L, Sanders NM, Dunn-Meynell AA. Neuronal glucosensing: what do we know after 50 years? Diabetes. 2004; 53:2521–8.

13. Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI. Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes. 1995; 44:180–4.

14. Aguayo-Mazzucato C, Zavacki AM, Marinelarena A, Hollister-Lock J, El Khattabi I, Marsili A, et al. Thyroid hormone promotes postnatal rat pancreatic β-cell development and glucose-responsive insulin secretion through MAFA. Diabetes. 2013; 62:1569–80.

15. Verga Falzacappa C, Mangialardo C, Madaro L, Ranieri D, Lupoi L, Stigliano A, et al. Thyroid hormone T3 counteracts STZ induced diabetes in mouse. PLoS One. 2011; 6:e19839.

16. Nishi M. Diabetes mellitus and thyroid diseases. Diabetol Int. 2018; 9:108–12.

17. Park EA, Jerden DC, Bahouth SW. Regulation of phosphoenolpyruvate carboxykinase gene transcription by thyroid hormone involves two distinct binding sites in the promoter. Biochem J. 1995; 309(Pt 3):913–9.

18. Park EA, Song S, Vinson C, Roesler WJ. Role of CCAAT enhancer-binding protein beta in the thyroid hormone and cAMP induction of phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem. 1999; 274:211–7.

19. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011; 2011:439463.

20. Klieverik LP, Janssen SF, van Riel A, Foppen E, Bisschop PH, Serlie MJ, et al. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc Natl Acad Sci U S A. 2009; 106:5966–71.

21. Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med. 1995; 12:622–7.

22. Kadiyala R, Peter R, Okosieme OE. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract. 2010; 64:1130–9.

23. Orzan A, Novac C, Mihu M, Tirgoviste CI, Balgradean M. Type 1 diabetes and thyroid autoimmunity in children. Maedica (Bucur). 2016; 11:308–12.

24. Roldan MB, Alonso M, Barrio R. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Diabetes Nutr Metab. 1999; 12:27–31.

25. Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care. 2003; 26:1181–5.

26. Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care. 2002; 25:1346–50.

27. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, et al. Autoantibody “subspecificity” in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005; 28:850–5.

28. Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev. 2008; 29:697–725.

29. Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev. 2019; 40:789–824.

30. Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, Tomer Y. Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab. 2009; 94:1458–66.

31. Tomer Y, Menconi F. Type 1 diabetes and autoimmune thyroiditis: the genetic connection. Thyroid. 2009; 19:99–102.

32. Frommer L, Kahaly GJ. Type 1 diabetes and autoimmune thyroid disease: the genetic link. Front Endocrinol (Lausanne). 2021; 12:618213.

33. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000; 160:1573–5.

34. British Thyroid Association, The Association for Clinical Biochemistry: UK guidelines for the use of thyroid function tests. Available from: http://www.british-thyroid-association.org/sandbox/bta2016/uk_guidelines_for_the_use_of_thyroid_function_tests.pdf (cited 2022 Feb 22).

35. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care. 2008; 31 Suppl 1:S12–54.

36. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002; 8:457–69.

37. National Institute for Health and Care Excellence: Type 1 diabetes in adults: diagnosis and management. Available from: https://www.nice.org.uk/guidance/ng17/resources/type-1-diabetesin-adults-diagnosis-and-management-pdf-1837276469701 (cited 2022 Feb 22).

38. Mahmud FH, Elbarbary NS, Frohlich-Reiterer E, Holl RW, Kordonouri O, Knip M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2018; 19(Suppl 27):275–86.

39. LeFevre ML; U.S. Preventive Services Task Force. Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015; 162:641–50.

40. Gierach M, Gierach J, Junik R. Insulin resistance and thyroid disorders. Endokrynol Pol. 2014; 65:70–6.

41. Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf). 2011; 75:1–9.

42. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 2007; 92:491–6.

43. Maxon HR, Kreines KW, Goldsmith RE, Knowles HC Jr. Long-term observations of glucose tolerance in thyrotoxic patients. Arch Intern Med. 1975; 135:1477–80.

44. O’Meara NM, Blackman JD, Sturis J, Polonsky KS. Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. J Clin Endocrinol Metab. 1993; 76:79–84.

45. Eledrisi MS, Alshanti MS, Shah MF, Brolosy B, Jaha N. Overview of the diagnosis and management of diabetic ketoacidosis. Am J Med Sci. 2006; 331:243–51.

46. Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. Endocr Pract. 2009; 15:254–62.

47. Tamez-Perez HE, Martinez E, Quintanilla-Flores DL, TamezPena AL, Gutierrez-Hermosillo H, Diaz de Leon-Gonzalez E. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population: an observational study. Med Clin (Barc). 2012; 138:475–7.

48. Distiller LA, Polakow ES, Joffe BI. Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy. Diabet Med. 2014; 31:172–5.

49. Al-Geffari M, Ahmad NA, Al-Sharqawi AH, Youssef AM, Alnaqeb D, Al-Rubeaan K. Risk factors for thyroid dysfunction among type 2 diabetic patients in a highly diabetes mellitus prevalent society. Int J Endocrinol. 2013; 2013:417920.

50. Chen G, Wu J, Lin Y, Huang B, Yao J, Jiang Q, et al. Associations between cardiovascular risk, insulin resistance, beta-cell function and thyroid dysfunction: a cross-sectional study in She ethnic minority group of Fujian Province in China. Eur J Endocrinol. 2010; 163:775–82.

51. Song F, Bao C, Deng M, Xu H, Fan M, Paillard-Borg S, et al. The prevalence and determinants of hypothyroidism in hospitalized patients with type 2 diabetes mellitus. Endocrine. 2017; 55:179–85.

52. Chaker L, Ligthart S, Korevaar TI, Hofman A, Franco OH, Peeters RP, et al. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. BMC Med. 2016; 14:150.

53. Joffe BI, Distiller LA. Diabetes mellitus and hypothyroidism: strange bedfellows or mutual companions? World J Diabetes. 2014; 5:901–4.

54. Dubaniewicz A, Kaciuba-Uscilko H, Nazar K, Budohoski L. Sensitivity of the soleus muscle to insulin in resting and exercising rats with experimental hypo- and hyper-thyroidism. Biochem J. 1989; 263:243–7.

55. Rochon C, Tauveron I, Dejax C, Benoit P, Capitan P, Fabricio A, et al. Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism. Clin Sci (Lond). 2003; 104:7–15.

56. Han C, He X, Xia X, Li Y, Shi X, Shan Z, et al. Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2015; 10:e0135233.

57. Ha J, Lee J, Lim DJ, Lee JM, Chang SA, Kang MI, et al. Association of serum free thyroxine and glucose homeostasis: Korea National Health and Nutrition Examination Survey. Korean J Intern Med. 2021; 36(Suppl 1):S170–9.

58. National Institute for Health and Care Excellence: Type 2 diabetes in adults: management. Available from: https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-inadults-management-1837338615493 (cited 2022 Feb 22).

59. American Diabetes Association. 3. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41:S28–37.

60. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012; 18:988–1028.

61. Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, et al. Other complications and associated conditions with diabetes in children and adolescents. Pediatr Diabetes. 2009; 10 Suppl 12:204–10.

62. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2009; 10 Suppl 12:17–32.

63. Konar H, Sarkar M, Roy M. Association of thyroid dysfunction and autoimmunity in pregnant women with diabetes mellitus. J Obstet Gynaecol India. 2018; 68:283–8.

64. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of maternal insulin resistance during pregnancy: an updated overview. J Diabetes Res. 2019; 2019:5320156.

65. Vannucchi G, Covelli D, Vigo B, Perrino M, Mondina L, Fugazzola L. Thyroid volume and serum calcitonin changes during pregnancy. J Endocrinol Invest. 2017; 40:727–32.

66. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017; 27:315–89.

67. Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab. 2004; 18:249–65.

68. Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab. 1992; 75:1333–7.

69. McCarthy FP, Lutomski JE, Greene RA. Hyperemesis gravidarum: current perspectives. Int J Womens Health. 2014; 6:719–25.

70. Rodien P, Bremont C, Sanson ML, Parma J, Van Sande J, Costagliola S, et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med. 1998; 339:1823–6.

71. Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018; 29:743–54.

72. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol. 2017; 13:610–22.

73. Dieguez M, Herrero A, Avello N, Suarez P, Delgado E, Menendez E. Prevalence of thyroid dysfunction in women in early pregnancy: does it increase with maternal age? Clin Endocrinol (Oxf). 2016; 84:121–6.

74. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A, et al. Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol (Oxf). 1991; 35:41–6.

75. Glinoer D. Thyroid hyperfunction during pregnancy. Thyroid. 1998; 8:859–64.

76. Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death. Thyroid. 2010; 20:989–93.

77. Gong LL, Liu H, Liu LH. Relationship between hypothyroidism and the incidence of gestational diabetes: a meta-analysis. Taiwan J Obstet Gynecol. 2016; 55:171–5.

78. Gallas PR, Stolk RP, Bakker K, Endert E, Wiersinga WM. Thyroid dysfunction during pregnancy and in the first postpartum year in women with diabetes mellitus type 1. Eur J Endocrinol. 2002; 147:443–51.

79. Gerstein HC. Incidence of postpartum thyroid dysfunction in patients with type I diabetes mellitus. Ann Intern Med. 1993; 118:419–23.

80. Maleki N, Tavosi Z. Evaluation of thyroid dysfunction and autoimmunity in gestational diabetes mellitus and its relationship with postpartum thyroiditis. Diabet Med. 2015; 32:206–12.

81. Toulis KA, Stagnaro-Green A, Negro R. Maternal subclinical hypothyroidsm and gestational diabetes mellitus: a metaanalysis. Endocr Pract. 2014; 20:703–14.

82. Knight BA, Shields BM, Hattersley AT, Vaidya B. Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters. Eur J Endocrinol. 2016; 174:51–7.

83. Bassols J, Prats-Puig A, Soriano-Rodriguez P, Garcia-Gonzalez MM, Reid J, Martinez-Pascual M, et al. Lower free thyroxin associates with a less favorable metabolic phenotype in healthy pregnant women. J Clin Endocrinol Metab. 2011; 96:3717–23.

84. Rawal S, Tsai MY, Hinkle SN, Zhu Y, Bao W, Lin Y, et al. A longitudinal study of thyroid markers across pregnancy and the risk of gestational diabetes. J Clin Endocrinol Metab. 2018; 103:2447–56.

85. Casey BM, Leveno KJ. Thyroid disease in pregnancy. Obstet Gynecol. 2006; 108:1283–92.

86. Yazbeck CF, Sullivan SD. Thyroid disorders during pregnancy. Med Clin North Am. 2012; 96:235–56.

87. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005; 105:239–45.

88. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999; 341:549–55.

89. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG, et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N Engl J Med. 2017; 376:815–25.

90. Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, Rees R, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012; 366:493–501.

91. Carney LA, Quinlan JD, West JM. Thyroid disease in pregnancy. Am Fam Physician. 2014; 89:273–8.

92. Yi KH, Kim KW, Yim CH, Jung ED, Chung JH, Chung HK, et al. Guidelines for the diagnosis and management of thyroid disease during pregnancy and postpartum. J Korean Thyroid Assoc. 2014; 7:7–39.

93. Thyroid disease in pregnancy: ACOG practice bulletin, number 223. Obstet Gynecol. 2020; 135:e261–74.

94. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010; 44:87–97.

95. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010; 62:956–65.

96. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006; 91:225–7.

97. Isidro ML, Penin MA, Nemina R, Cordido F. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine. 2007; 32:79–82.

98. Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care. 2009; 32:1589–90.

99. Lupoli R, Di Minno A, Tortora A, Ambrosino P, Lupoli GA, Di Minno MN. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab. 2014; 99:E143–8.

100. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res. 2019; 11:3295–313.

101. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014; 20:953–66.

102. Muaddi H, Chowdhury S, Vellanki R, Zamiara P, Koritzinsky M. Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol. 2013; 108:446–50.

103. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord. 2011; 9:69–75.

104. Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, et al. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 2012; 19:447–56.

105. Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012; 97:E510–20.

106. Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013; 98:3269–79.

107. Cho SW, Yi KH, Han SK, Sun HJ, Kim YA, Oh BC, et al. Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 2014; 393:24–9.

108. Cho YY, Kang MJ, Kim SK, Jung JH, Hahm JR, Kim TH, et al. Protective effect of metformin against thyroid cancer development: a population-based study in Korea. Thyroid. 2018; 28:864–70.

109. Brown J, Solomon DH. Mechanism of antithyroid effects of a sulfonylurea in the rat. Endocrinology. 1958; 63:473–80.

110. Nikkila EA, Jakobson T, Jokipii SG, Karlsson K. Thyroid function in diabetic patients under long-term sulfonylurea treatment. Acta Endocrinol (Copenh). 1960; 33:623–9.

111. Tranquada RE, Solomon DH, Brown J, Greene R. The effect of oral hypoglycemic agents on thyroid function in the rat. Endocrinology. 1960; 67:293–7.

112. England ML, Hartnell JM, Hershman JM, Levin SR. Glyburide does not alter thyroid function. Diabetes Res. 1986; 3:471–4.

113. Ikeda T, Ito Y, Murakami I, Mokuda O, Tokumori Y, Tominaga M, et al. Effect of glibenclamide on thyroid hormone metabolism in rats. Horm Metab Res. 1986; 18:517–20.

114. Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJ. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018; 77:548–67.

115. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351:1106–18.

116. Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenga S. Peroxisome proliferator-activated receptor-γ in thyroid autoimmunity. PPAR Res. 2015; 2015:232818.

117. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002; 87:2352–8.

118. Lee S, Tsirbas A, Goldberg RA, McCann JD. Thiazolidinedione induced thyroid associated orbitopathy. BMC Ophthalmol. 2007; 7:8.

119. Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol (Oxf). 2006; 65:35–9.

120. Tseng CH. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Ann Med. 2013; 45:539–44.

121. Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagonlike peptide 1. FEBS Lett. 1996; 393:248–52.

122. Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology. 1996; 137:3674–80.

123. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151:1473–86.

124. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies: review of the scientific evidence. J Clin Endocrinol Metab. 2011; 96:2027–31.

125. Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011; 96:853–60.

126. Sencar ME, Sakiz D, Calapkulu M, Hepsen S, Kizilgul M, Ozturk IU, et al. The effect of exenatide on thyroid-stimulating hormone and thyroid volume. Eur Thyroid J. 2019; 8:307–11.

127. Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbol JD, et al. No evidence of increase in calcitonin concentrations or development of c-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial. Diabetes Care. 2018; 41:620–2.

128. Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7:24871–9.

129. Okada J, Yamada E, Niijima Y, Okada S, Yamada M. Dipeptidyl peptidase-4 inhibitors attenuate thyroid-stimulating hormone concentrations. J Diabetes. 2019; 11:497.

130. Bays HE. Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int J Gen Med. 2014; 7:355–64.

131. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008; 168:1531–40.

132. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009; 7:255–8.

133. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J. 2007; 54:53–8.

134. Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011; 34(Suppl 2):S244–50.

135. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010; 12:384–92.

136. Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1993; 38:39–43.

137. Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm. 2002; 59:932–9.

138. Rameshwar J, Anand K. Antihyperglycaemic and antiperoxidative roles of acarbose in type 2 diabetes mellitus are possibly mediated through changes in thyroid function. Clin Exp Pharmacol Physiol. 2006; 33:1104–6.

139. Li C, Kuang J, Zhao Y, Sun H, Guan H. Effect of type 2 diabetes and antihyperglycemic drug therapy on signs of tumor invasion in papillary thyroid cancer. Endocrine. 2020; 69:92–9.

140. De Jonghe S, Proctor J, Vinken P, Feyen B, Wynant I, Marien D, et al. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact. 2014; 224:1–12.

141. Taub ME, Ludwig-Schwellinger E, Ishiguro N, Kishimoto W, Yu H, Wagner K, et al. Sex-, species-, and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (M466/2) that degrades to 4-hydroxycrotonaldehyde, a reactive and cytotoxic species. Chem Res Toxicol. 2015; 28:103–15.

142. Cryer PE. Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol. 1993; 264(2 Pt 1):E149–55.

143. Demitrost L, Ranabir S. Thyroid dysfunction in type 2 diabetes mellitus: a retrospective study. Indian J Endocrinol Metab. 2012; 16(Suppl 2):S334–5.

144. Katz HP, Youlton R, Kaplan SL, Grumbach MM. Growth and growth hormone. 3. Growth hormone release in children with primary hypothyroidism and thyrotoxicosis. J Clin Endocrinol Metab. 1969; 29:346–51.

145. Kamilaris TC, DeBold CR, Pavlou SN, Island DP, Hoursanidis A, Orth DN. Effect of altered thyroid hormone levels on hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab. 1987; 65:994–9.

146. McCulloch AJ, Johnston DG, Baylis PH, Kendall-Taylor P, Clark F, Young ET, et al. Evidence that thyroid hormones regulate gluconeogenesis from glycerol in man. Clin Endocrinol (Oxf). 1983; 19:67–76.

147. McDaniel HG, Pittman CS, Oh SJ, DiMauro S. Carbohydrate metabolism in hypothyroid myopathy. Metabolism. 1977; 26:867–73.

148. Clausen N, Lins PE, Adamson U, Hamberger B, Efendic S. Counterregulation of insulin-induced hypoglycaemia in primary hypothyroidism. Acta Endocrinol (Copenh). 1986; 111:516–21.

149. Muller MJ, Seitz HJ. Interrelation between thyroid state and the effect of glucagon on gluconeogenesis in perfused rat livers. Biochem Pharmacol. 1987; 36:1623–7.